[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital of Macerata\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100531496","aron-3-study-international-multicentric-retrospective-study-to-collect-global-experiences-in-the-treatment-of-patients-with-metastatic-pca-100531496",false,"NCT06200558","ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of PC\n* Histologically or radiologically confirmed diagnosis of metastatic disease and\n\nFor ARON-3S\n\n▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)\n\nFor ARON-3Lu\n\n▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC\n\nFor ARON-3GEN\n\n* HRD POSITIVE STATUS\n* Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of PC\n* Patients without histologically or radiologically confirmed metastatic disease and\n\nFor ARON-3S\n\n▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section\n\nFor ARON-3Lu\n\n▪ Patients treated with Luthetium-177-PSMA therapy for hormone\u002Fcastration sensitive PC\n\nFor ARON-3GEN\n\n* HRD NEGATIVE STATUS\n* Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study","ALL","18 Years",{"count":18,"type":19},534,"ESTIMATED","OBSERVATIONAL","Study wants to explore real-world data in three distinct settings\n\n* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \\_ARON-3S\n* Patients receiving Lutetium-177 PSMA for mCRPC \\_ ARON-3Lu\n* Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \\_ ARON-3GEN",[23],"Prostate Cancer",[25,26,27,28,29],"mCSPC","Lutetium-177 PSMA","PARP inhibitors","ADT","ARSI","RECRUITING","2025-11-19",{"date":33,"type":34},"2025-11-26","ACTUAL",{"date":36,"type":34},"2024-01-31",{"date":38,"type":19},"2028-02-01",{"name":40,"class":41},"Hospital of Macerata","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":60,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":42},"100461347","international-multicentric-study-aron-1-100461347","NCT05287464","International Multicentric Study ARON-1","Inclusion Criteria:\n\n* Patients aged \\>18y\n* Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC\n* Histologically or radiologically confirmed diagnosis of metastatic disease\n* First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab\n\nExclusion Criteria:\n\n* Patients without histologically confirmed diagnosis of RCC\n* Patients without histologically or radiologically confirmed metastatic disease\n* Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section",{"count":50,"type":19},1220,"The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.\n\nTwo Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations",[53],"Metastatic Renal Cell Carcinoma (mRCC)",[55,56,57,58,59],"immunotherapy","mRCC","immuno-combinations","artificial intelligence technology","real-world data",{"date":33,"type":34},{"date":62,"type":34},"2022-03-10",{"date":64,"type":19},"2027-09-30",{"name":40,"class":41},""]